Here, by developing a syngeneic mouse ROR1 (mROR1) tumor model [25], we investigated the immunogenicity of mROR1, as a murine TAA, and four different ROR1 fusion proteins containing different carriers and tags and also assessed the protective efficacy of the fusion proteins as anti-cancer candidate vaccine. The gene discussed is ROR1; the disease is cancer.